Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma

Liu,Siming; Deng,Xiaojun; Zhang,Jiong

doi:10.3892/mmr.2019.10762

Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma

Authors:
- Siming Liu
- Xiaojun Deng
- Jiong Zhang
View Affiliations

Affiliations: Department of Urology, Zhoupu Hospital Affiliated with Shanghai University of Medicine and Health Sciences, Shanghai 200000, P.R. China, Department of Urology, Shanghai Putuo District Liqun Hospital, Shanghai 200000, P.R. China
Published online on: October 22, 2019 https://doi.org/10.3892/mmr.2019.10762
Pages: 5075-5083
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clear cell renal cell carcinoma (ccRCC), the most common subtype, accounts for approximately 80% of all RCC cases. ccRCC patients typically present with an advanced stage at the time of diagnosis resulting in a poor patient prognosis. The present study aimed to identify novel potential microRNAs (miRNAs or miRs) in peripheral blood as biomarkers for the detection of ccRCC. Candidate miRNAs were selected through integrated analysis of the Gene Expression Omnibus (GEO) database, The Cancer Genome Atlas (TCGA) database, and from clinical samples. The expression levels of miRNAs were quantified using reverse transcription‑quantitative PCR. Receiver operating characteristic (ROC) curve analysis was used to explore the diagnostic values of the miRNAs. Bioinformatic analysis of candidate miRNAs was conducted by using the STRING database. After an integrated analysis of the GEO and TCGA databases, four miRNAs were found to be consistently dysregulated in ccRCC tissues. Then, their expression levels in serum and diagnostic utilities were further explored. We discovered that serum miR‑508‑3p and miR‑885‑5p were significantly dysregulated in ccRCC patients with marked diagnostic values. The area under the ROC curve (AUC) of serum miR‑508‑3p and miR‑885‑5p was 0.80 (95% CI, 0.73‑0.87) and 0.87 (95% CI, 0.79‑0.95), respectively. Functional enrichment analysis revealed that both miR‑508‑3p and miR‑885‑5p were closely associated with cellular metabolic processes. In conclusion, serum miR‑508‑3p and miR‑885‑5p are novel potential biomarkers for the diagnosis of ccRCC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Bhatt JR and Finelli A: Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol. 11:517–525. 2014. View Article : Google Scholar : PubMed/NCBI
4	White NM, Khella HW, Grigull J, Adzovic S, Youssef YM, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA, et al: miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer. 105:1741–1749. 2011. View Article : Google Scholar : PubMed/NCBI
5	Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC and Blute ML: Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: Indications and recommendations for surgical templates. Eur Urol. 59:18–23. 2011. View Article : Google Scholar : PubMed/NCBI
6	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
7	Lovat F, Valeri N and Croce CM: MicroRNAs in the pathogenesis of cancer. Semin Oncol. 38:724–733. 2011. View Article : Google Scholar : PubMed/NCBI
8	Jiang L, Lv L, Liu X, Jiang X, Yin Q, Hao Y and Xiao L: MiR-223 promotes oral squamous cell carcinoma proliferation and migration by regulating FBXW7. Cancer Biomark. 24:325–334. 2019. View Article : Google Scholar : PubMed/NCBI
9	Liu X, Wang J and Zhang G: miR-4458 regulates cell proliferation and apoptosis through targeting SOCS1 in triple-negative breast cancer. J Cell Biochem. 120:12943–12948. 2019. View Article : Google Scholar : PubMed/NCBI
10	Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, et al: Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 38:100–112. 2018. View Article : Google Scholar : PubMed/NCBI
11	Liu X, Xu T, Hu X, Chen X, Zeng K, Sun L and Wang S: Elevated circulating miR-182 acts as a diagnostic biomarker for early colorectal cancer. Cancer Manag Res. 10:857–865. 2018. View Article : Google Scholar : PubMed/NCBI
12	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
13	Emami SS, Nekouian R, Akbari A, Faraji A, Abbasi V and Agah S: Evaluation of circulating miR-21 and miR-222 as diagnostic biomarkers for gastric cancer. J Cancer Res Ther. 15:115–119. 2019.PubMed/NCBI
14	Sun Y, Yang B, Lin M, Yu H, Chen H and Zhang Z: Identification of serum miR-30a-5p as a diagnostic and prognostic biomarker in colorectal cancer. Cancer Biomark. 24:299–305. 2019. View Article : Google Scholar : PubMed/NCBI
15	Butz H, Nofech-Mozes R, Ding Q, Khella HWZ, Szabó PM, Jewett M, Finelli A, Lee J, Ordon M, Stewart R, et al: Exosomal MicroRNAs are diagnostic biomarkers and can mediate cell-cell communication in renal cell carcinoma. Eur Urol Focus. 2:210–218. 2016. View Article : Google Scholar : PubMed/NCBI
16	Lou N, Ruan AM, Qiu B, Bao L, Xu YC, Zhao Y, Sun RL, Zhang ST, Xu GH, Ruan HL, et al: miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma. Urol Oncol. 35:36.e7–e36.e14. 2017. View Article : Google Scholar
17	Chen X, Lou N, Ruan A, Qiu B, Yan Y, Wang X, Du Q, Ruan H, Han W, Wei H, et al: miR-224/miR-141 ratio as a novel diagnostic biomarker in renal cell carcinoma. Oncol Lett. 16:1666–1674. 2018.PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Dai M, Li L and Qin X: Clinical value of miRNA-122 in the diagnosis and prognosis of various types of cancer. Oncol Lett. 17:3919–3929. 2019.PubMed/NCBI
20	Fang H, Liu Y, He Y, Jiang Y, Wei Y, Liu H, Gong Y and An G: Extracellular vesicle-delivered miR5055p, as a diagnostic biomarker of early lung adenocarcinoma, inhibits cell apoptosis by targeting TP53AIP1. Int J Oncol. 45:1821–1832. 2019.
21	Moya L, Meijer J, Schubert S, Matin F and Batra J: Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 expression as biomarker for prostate cancer diagnosis. Int J Mol Sci. 20(pii): E11542019. View Article : Google Scholar : PubMed/NCBI
22	Tan HY, Zheng YB and Liu J: Serum miR-199a as a potential diagnostic biomarker for detection of colorectal cancer. Eur Rev Med Pharmacol Sci. 22:8657–8663. 2018.PubMed/NCBI
23	Guo J, Liu C, Wang W, Liu Y, He H, Chen C, Xiang R and Luo Y: Identification of serum miR-1915-3p and miR-455-3p as biomarkers for breast cancer. PLoS One. 13:e02007162018. View Article : Google Scholar : PubMed/NCBI
24	Guo SJ, Zeng HX, Huang P, Wang S, Xie CH and Li SJ: MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer. Eur Rev Med Pharmacol Sci. 22:6379–6385. 2018.PubMed/NCBI
25	Huang T, Kang W, Zhang B, Wu F, Dong Y, Tong JH, Yang W, Zhou Y, Zhang L, Cheng AS, et al: miR-508-3p concordantly silences NFKB1 and RELA to inactivate canonical NF-κB signaling in gastric carcinogenesis. Mol Cancer. 15:92016. View Article : Google Scholar : PubMed/NCBI
26	Zhai Q, Zhou L, Zhao C, Wan J, Yu Z, Guo X, Qin J, Chen J and Lu R: Identification of miR-508-3p and miR-509-3p that are associated with cell invasion and migration and involved in the apoptosis of renal cell carcinoma. Biochem Biophys Res Commun. 419:621–626. 2012. View Article : Google Scholar : PubMed/NCBI
27	Yu FQ, Wang Z, Wang XW, Wang SL, Li XD, Huang QS and Lin JH: MicroRNA-885-5p promotes osteosarcoma proliferation and migration by downregulation of cell division cycle protein 73 homolog expression. Oncol Lett. 17:1565–1572. 2019.PubMed/NCBI
28	Dickerman BA, Torfadottir JE, Valdimarsdottir UA, Wilson KM, Steingrimsdottir L, Aspelund T, Batista JL, Fall K, Giovannucci E, Sigurdardottir LG, et al: Midlife metabolic factors and prostate cancer risk in later life. Int J Cancer. 142:1166–1173. 2018. View Article : Google Scholar : PubMed/NCBI
29	Tan W, Zhong Z, Wang S, Liu H, Yu H, Tan R, Hu X, Pan T and Wang Y: The typical metabolic modifiers conferring improvement in cancer resistance. Curr Med Chem. 24:3698–3710. 2017. View Article : Google Scholar : PubMed/NCBI
30	Rinaldi G, Rossi M and Fendt SM: Metabolic interactions in cancer: Cellular metabolism at the interface between the microenvironment, the cancer cell phenotype and the epigenetic landscape. Wiley Interdiscip Rev Syst Biol Med. Aug 30;20172doi: doi.org/10.1002/wsbm.1397.
31	Zhang J, Ye Y, Chang DW, Lin SH, Huang M, Tannir NM, Matin S, Karam JA, Wood CG, Chen ZN and Wu X: Global and targeted miRNA expression profiling in clear cell renal cell carcinoma tissues potentially links miR-155-5p and miR-210-3p to both tumorigenesis and recurrence. Am J Pathol. 188:2487–2496. 2018. View Article : Google Scholar : PubMed/NCBI